Research programme: adult stem cell therapeutics - TiGenixAlternative Names: Cx 602; Cx 603
Latest Information Update: 22 Dec 2011
At a glance
- Originator Cellerix
- Developer TiGenix
- Class Stem cell therapies
- Mechanism of Action Cell replacements; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Osteoarthritis; Rheumatoid arthritis